When Worlds Collide: The Theory of Real-World Evidence Meets Reality
FDA Law Blog: Biosimilars
MAY 13, 2024
It was Congress that intervened in 2022, to mandate FDA to issue or revise its 2017 guidance on considerations for the use of RWD and RWE to support regulatory decision-making for devices to clarify its regulatory expectations. This guidance, when finalized, will replace the original version of this document finalized in 2017.
Let's personalize your content